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op t i m i z i n g  M u l t i p l e  A n a l y t e  
I n j e c t i o n s  i n  su r f a c e  pl a s m o n  
Re s o n a n c e  B i o s e n s o r s  w i t h  
Analytes having Different 
Re f r a c t i v e  I n d e x  I n c r e m e n t s
M a s s i n i s s a  si  M e h a n d ,  B a l a sr i n i v s a n* &  G r e g o r y D e  C r e s c e n z o*
su r f a c e  p l a s m o n  r e s o n a n c e - b a s e d  b i o s e n s o r s  h a v e  b e e n  s u c c e s s f u l l y  a p p l i e d  t o  t h e  s t u d y  o f  t h e  
interactions between macromolecules and small molecular weight compounds. In an effort to 
i n c r e a s e  t h e  t h r o u g h p u t  o f  t h e s e  spR- b a s e d  e x p e r i m e n t s ,  w e  h a v e  a l r e a d y  p r o p o s e d  t o  i n j e c t  
multiple compounds simultaneously over the same surface. When specifically applied to small 
m o l e c u l a r  w e i g h t  c o m p o u n d s ,  s u c h  a  s t r a t e g y  w o u l d  h o w e v e r  r e q u i r e  p r i o r  k n o w l e d g e  o f  t h e  
r e f r a c t i v e  i n d e x  i n c r e m e n t  o f  e a c h  c o m p o u n d  i n  o r d e r  t o  c o r r e c t l y  i n t e r p r e t  t h e  r e c o r d e d  s i g n a l .  A n  
a d d i t i o n a l  e x p e r i m e n t  i s  t y p i c a l l y  r e q u i r e d  t o  o b t a i n  t h i s  i n f o r m a t i o n .  I n  t h i s  m a n u s c r i p t ,  w e  s h o w  
t h a t  t h r o u g h  t h e  i n t r o d u c t i o n  o f  a n  a d d i t i o n a l  g l o b a l  p a r a m e t e r  c o r r e s p o n d i n g  t o  t h e  r a t i o  o f  t h e  
saturating signals associated with each molecule, the kinetic parameters could be identified with 
similar confidence intervals without any other experimentation.
Within the last decades, Surface Plasmon Resonance (SPR)-based biosensors have evolved to become 
an almost indispensable tool for the rigorous investigation of the interactions occurring between bio-
molecules1,2. e applications SPR biosensors to drug screening has already been acknowledged3 and 
their ever-growing popularity in this area is most likely related to the high sensitivity the recent SPR 
biosensors have reached, the high degree of automation as well as the availability of robust data analysis 
soware packages that ease subsequent data analysis4–6.
In order to satisfy the throughput capacity required for drug screening campaigns (e.g. for frag-
ment libraries7), most of the latest SPR-based biosensor developments have been directed to provide 
researchers with tools combining the exibility and information-rich measurements of SPR devices to 
the high-throughput capacity of standard in vitro assays such as ELISA8. In this endeavour, SPR bio-
sensing platforms being able to inject one sample against hundreds of immobilized targets, or multiple 
samples on multiple surfaces are now available. However, in most cases, the throughput capacity of 
these platforms is detrimental to the condence level one can get on the kinetic parameters: classical 
low throughput SPR instruments still remain the most appropriate tools for precise kinetic parameter 
determination. A classical experiment with these instruments consists of 5-to-10 analyte injections. Of 
interest, Ö’nell and Andersson have demonstrated that two injections, when adequately chosen, allow for 
kinetic parameter determination with similar condence as that of resulting from classical experiments9. 
With that in mind, our group has then developed an iterative optimisation algorithm aiming to reduce 
experimental time and material consumption under the desired condence on kinetic parameters10. 
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Recently, we went one step further by introducing an experimentation strategy based on simultaneous 
injections of two analytes combined with numerical optimization6. We demonstrated that this method 
further improves the throughput of the SPR while reducing material consumption. In this approach, the 
interactions between analytes and a given ligand had been modelled by assuming that the amplitude of 
the signal corresponding to each analyte was proportional to the mass accumulation on the surface, as 
already assumed by others11–14. is assumption is valid when the refractive index increments (RII) of 
the analytes are identical. Such is the case for proteins, for which RII values are around 0.18–0.19 ml/g. 
However, this hypothesis may not hold true for heavily glycosylated proteins, carbohydrates or small 
molecular weight compounds, for which RII values diering by up to two folds have been observed15. 
As reported by Davis and Wilson (2000), the impact of these RII discrepancies upon SPR measurements 
can be taken into account by determining the RII of the compounds with a dierential refractometer. 
In an SPR-based screening campaign, the determination of the RII of each individual drug, prior to 
multiple-analyte injections would however signicantly slow down the screening process. In this paper, 
we demonstrate that this issue can be alleviated by the use of an additional global parameter (α ). is 
parameter corresponds to the ratio of the saturation levels (Rmax) of the molecules under investigation 
and thus takes into account RII discrepancies. We here demonstrate that this strategy is ecient to 
determine kinetic parameters since deviations of less than 10% were obtained when compared to values 
deduced from a standard experimental procedure (injection of one analyte at a time) while completely 
avoiding the experimentation required to calculate the RII of each individual drug.
M a t e r i a l s  a n d  M e t h o d s
M a t e r i a l s .  Experimental data sets were generated with a BIACORE T100 optical biosensor equipped 
with research-grade CM5 sensor chips (GE Healthcare, Baie d’Urfe, QC). HBS-EP buer, acetate buer 
and ethanolamine were purchased from GE Healthcare. N-ethyl-N’-(3-dimethylaminopropyl) carbo-
diimide (EDC), N-hydroxysuccinimide (NHS), carbonic anhydrase isozyme II (CAII) that had been 
puried from bovine erythrocytes, 4-carboxybenzenesulfonamide (CBS), sulfanilamide, 1,3-benzene-
disulfonamide (BDS), Sulpiride, Furosemide, 5-dimethyl-amino-1-naphthalene-sulfonamide (DNSA), 
dimethyl sulfoxide (DMSO) and phosphate buer saline (PBS, 10 mM, pH 7.4) were purchased from 
Sigma-Aldrich Canada Ltd (Oakville, ON).
B i o s e n s o r  s u r f a c e  p r e p a r a t i o n . Biosensor surface preparation (CAII and blank surfaces) were per-
formed according to published protocols16. CAII surface was prepared at density of approximately 5000 
RU. Aer CAII immobilization or blank surface generation, the system was extensively primed with 
running buer (HBS-EP).
B I A C oRe s a m p l e  i n j e c t i o n s . A alyte and buer preparations. Analytes and buer were prepared 
according to protocol reported in Navratilova et al. (2007). HBS-EP with 3% of DMSO was used as a 
running buer. All the analytes were dissolved in pure DMSO ([CBS] = 1.76 mM, [BDS] = 0.35 mM, 
[sulphanilamide] = 1.67 mM, [Sulpiride] = 9.19 mM, [Furosemide] = 8.4205 mM, [DNSA] = 1.97 mM). 
ese stocks were diluted by mixing 30 µ l with 970 µ l of pure HPS-EP, resulting in concentrations of 
52.98 µ M, 10. 49 µ M, 50.27 µ M, 275.81 µ M, 252.61 µ M and 59.10 µ M for each analyte, respectively with 
3% of DMSO in order to match the amount of DMSO in the running buer.
Single analyte injections. Prior to analyte injections, 3 prime procedures and buer injections were 
performed to stabilize the baseline of the instrument. All injections were performed in duplicate at a 
ow rate of 100 µ l/min with a data collection rate set at 10 Hz, at 18 °C. For preliminary classical kinetic 
experiments, CBS, BDS, sulphanilamide, sulpiride and furosemide samples were injected at concentra-
tions comprised between 264.90 nM and 52.98 µ M, 52.45 nM and 10.49 µ M, 251.37 nM and 50.27 µ M, 
1.37 µ M and 275.81 µ M or 315.80 nM and 252.61 µ M respectively, in addition to 6 buer solutions (for 
double referencing purpose), for 60 s across both control and CAII surfaces, followed by a maximum of 
350 s injection of HBS-EP running buer at 18 °C. As complete dissociation was observed in each case, 
no regeneration procedure was performed, in agreement with previous reports16,17.
Multiple analyte injections. Analytes were combined at dierent temperatures to create 11 case studies 
(including the case studies reported in6) as shown in Table 1. For each case study, 13 injections corre-
sponding to various mixtures of drugs were chosen to cover the dimension space for concentrations 
(Fig. 1).
D a t a  a n a l y s i s . In the ca e of classical injections (single-analyte injections), data sets were analyzed 
with Biacore T100 evaluation soware, Biaevaluation 1.1.1, for kinetic parameter determination. For 
multiple-analyte injections and optimized-experiment analysis, in-house soware packages were devel-
oped with the MATLAB 7.7.0.471 (R2008b) soware platform (e Mathworks, Natick, USA). ose 
include the soware package already described in the manuscript of Mehand et al. (2012) as well as 
the new multiple-analyte injection model that will be presented in detail in the subsequent sections. 
e optimization was solved with the standard simplex program available in the optimization Toolbox 
4.1 of Matlab. In the case of multiple-analyte injections, for fast and sure convergence, the sensorgrams 
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corresponding to the injection of single analytes at their highest concentrations ((CAmax, 0) and (0, CCmax)) 
were tted rst with a simple Langmuirian model. e resulting parameter values were taken as a starting 
point to t all the data.
Experiment
Individual 
compound
Model #1 
α = MM
1
2
Model #2 
α = RR
max1
max2
Model #3  
Free parameter αt αexp
CBS/Sulfanilamide (18 °C)
CBS 17.3%/7.6% 2.5%/3.4% 5.1%/0.03%
0.89 0.89
Sulfanilamide 19.6%/15.2% 2.1%/1.3% 1.2%/1.5%
BDS/Sulfanilamide (12 °C)
BDS 34.8%/19.2% 1.1%/1.8% 0.1%/2.4%
0.95 0.95
Sulfanilamide 54.3%/13.6% 4.1%/1.1% 5.7%/1.6%
CBS/Sulfanilamide (12 °C)
CBS 11.0%/1.3% 1.5%/2.8% 2.9%/0.6%
1.07 1.07
Sulfanilamide 9.0%/29.5% 2.2%/5.8% 1.7%/7.8%
CBS/BDS (12 °C)
CBS 17.0%/4.3% 4.5%/1.5% 5.5%/3.8%
1.02 1.03
BDS 19.6%/8.6% 1.2%/2.5% 1.1%/2.0%
CBS/Sulpiride (18 °C)
CBS 19.3%/0.8% 4.4%/0.8% 5.9%/0.3%
0.59 0.61
Sulpiride 49.3%/5.1% 0.3%/4.5% 0.6%/5.2%
BDS/Sulpiride (18 °C)
CBS 18.5%/2.0% 4.1%/3.8% 5.5%/5.1%
0.51 0.53
Sulpiride 40.0%/2.9% 3.6%/5.6% 3.5%/6.8%
Sulfanilamide/Sulpiride (18 °C)
Sulfanilamide 13.9%/6.1% 6.2%/7.2% 8.1%/8.0%
0.50 0.51
Sulpiride 6.0%/4.1% 7.4%/4.2% 9.4%/6.7%
CBS/Furosemide (18 °C)
CBS 21.8%/12.7% 7.2%/5.5% 5.0%/9.5%
0.52 0.51
Furosemide 1.7%/8.5% 3.7%/8.1% 4.3%/9.6%
BDS/Furosemide (18 °C)
BDS 49.5%/4.0% 7.5%/4.6% 6.1%/6.2%
0.54 0.55
Furosemide 5.0%/10.6% 5.8%/7.4% 6.9%/8.9%
Sulfanilamide/Furosemide (18 °C) Sulfanilamide 43.1%/14.6% 7.3%/6.2% 8.9%/5.9%
0.57 0.58
Furosemide 12.4%/9.4% 8.4%/9.1% 9.7%/9.2%
Sulpiride/Furosemide (18 °C)
Sulpiride 28.2%/8.0% 1.2%/3.1% 0.3%/2.7%
1.14 1.13
Furosemide 2.6%/2.9% 3.8%/2.7% 4.1%/3.1%
Table 1. Observed kinetic parameter deviation related to the use of the dierent models. For each 
scenario, observed deviations of the kinetic parameters (ka, kd) from those determined using a classical 
single-analyte injection approach, are given. α t corresponds to α , as deduced from the global t of the 
various sets of sensorgrams. α exp corresponds to the ratio of the plateau values (Rmax) corresponding to 
single-analyte injections that were performed at saturating concentrations.
Figure 1. Experimental strategy for multiple-analyte injection experiments. For a given couple 
of molecules (denoted A and C), each cross corresponds to an injected mixture of A and C at nal 
concentration indicated on the abscissa and ordinate, respectively. Minimal (i.e., CAmin, CCmin) and maximal 
(i.e., CAmax, CCmax) concentration values were identical to those used when injecting each drug individually 
(as indicated in the ‘Single analyte injections’ paragraph of the ‘Materials and Methods’ section).
w w w .n a t u re.c o m /sc i en t i f i c repo rt s/
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Re s u l t s
si g n a l - t o - m o l e c u l a r  w e i g h t  s t u d y . In order to test exten ively our multiple-analyte injection strategy 
while taking into account RII discrepancies, carbonic anhydrase isozyme II (CAII) was rst immobilized 
at the surface of our SPR biosensor. CAII was selected since its interactions with many small molecular 
weight compounds have already been extensively characterized. Among known and well-characterized 
CAII binders, CBS, BDS, DNSA, sulphanilamide, sulpiride and furosemide were selected to cover a broad 
range of molecular weight (from 172 to 341.43 g/mol) and kinetic constants (Table 2). Each compound, 
known to interact according to a 1:1 stoichiometry with CAII, was injected at a concentration allow-
ing to reach saturation at 18 °C, i.e., [CBS] = 52.98 µ M, [BDS] = 10.49 µ M, [Sulphanilamide] = 50.27 µ M, 
[Sulpiride] = 275.81 µ M, [Furosemide] = 252.61 µ M, [DNSA] = 59.10 µ M16–19. e plateau value of the 
resulting double-referenced sensorgrams corresponding to surface saturation was then plotted against 
their molecular weight in order to evaluate RII discrepancies. As can be seen in Fig. 2, there is no linear 
correlation between the molecular weight and the SPR signal for these small molecular compounds, 
thus indicating that most compounds had dierent RIIs. For example, CBS displayed saturation signals 
lower than sulphanilamide although sulphanilamide molecular weight is 14.51% lower than that of CBS. 
e same observation can be made for furosemide that gave a saturation level being lower than those of 
sulpiride and DNSA, in spite of their higher molecular weights.
In order to take into account these RIIs dierences when combining multiple analytes, we thus pro-
posed a new way to analyze sensorgrams resulting from multiple-analyte injections. In our approach, the 
ratio of the saturation levels of each analyte is estimated (α , global parameter) rather than experimentally 
determined with a dierential refractometer, as previously proposed15. is model is described in the 
eory section below.
th e o r y .  Assuming that both analytes A and C interact with the immobilized ligand (B) according to 
a simple 1:1 interaction model, their simultaneous injection results in the formation of two non-covalent 
complexes denoted AB and CB; the overall process being described by the following scheme:
Temperature 12 °C 18 °C
ka (×104 M−1s−1) kd (×10−3 s−1) ka (×104 M−1s−1) kd (×10−3 s−1)
BDS 7.86 ± 0.01 42.70 ± 0.04 10.87 ± 0.04 64.9 ± 0.3
CBS 2.23 ± 0.01 8.76 ± 0.02 2.75 ± 0.01 17.90 ± 0.04
Sulfanilamide 1.335 ± 0.005 34.3 ± 0.1 1.77 ± 0.01 68.7 ± 0.3
Sulpiride – – 0.26 ± 0.001 238 ± 2.5
Furosemide – – 3.90 ± 0.02 28.0 ± 0.2
Table 2. Kinetic parameters derived from single analyte experiments.
Figure 2. Observed saturation values (Rmax) as a function of the molecular weights of each analyte used 
in this study. Rmax values were determined on a single CAII surface (5000 RU) in duplicate.
w w w .n a t u re.c o m /sc i en t i f i c repo rt s/
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where ka1 and ka2 correspond to the related association rate constants (in M−1s−1), while kd1 and kd2 are 
the dissociation rate constants of the interactions (in s−1). e monitored signal thus corresponds to both 
ligand-analyte complexes (AB and CB) and the overall kinetics are described by the set of dierential 
equations (1) and (2):
= ( − − ) − , ( ) = ( )
dC
dt
k C C C C k C C 0 0 1
AB
a A B AB CB d AB AB1 0 1
= ( − − ) − , ( ) = ( )
dC
dt
k C C C C k C C 0 0 2
CB
a C B AB CB d CB CB2 0 2
where CA and CC correspond to the concentrations of free analyte A and C, respectively; CB0 is the con-
centration of the ligand B at the beginning of the interaction, CAB and CCB are the concentration of the 
complexes AB and CB respectively (in M).
δ β δ β= , = , = =C R C R C R or C RIf AB CB B B1 2 0 max1 0 max2
en, equations (1) and (2) are equivalent to equations (3) to (5)
β
δ
=


 − −


 − , ( ) = ( )
dR
dt
k C R R R k R R 0 0 3a A d
1
1 max1 1 2 1 1 1
δ
β
=



− −



− , ( ) =
( )
dR
dt
k C R R R k R R 0 0
4a C d
2
2 max1 1 2 2 2 2
= + ( )R R R 5T 1 2
Since
δ β α
β
δ
= = ⇒ = =
( )
C R R
R
R 6B0 max1 max2
max1
max2
Where δ and β are proportionality constants related to analytes A and C respectively. ese proportional-
ity constants are used to translate AB and AC concentrations into corresponding SPR responses (R1 and 
R2, respectively). RT, Rmax1 and Rmax2 correspond to the recorded SPR signal over time and to saturating 
values for drug A and C, respectively.
M o d e l  v a l i d a t i o n . Injections of various analyte pairs, i.e., (CBS, sulpiride), (CBS, furosemide), (BDS, 
sulpiride), (BDS, furosemide), (sulphanilamide, sulpiride), (sulphanilamide, furosemide) and (sulpiride, 
furosemide) were performed at 18 °C according to the experimental plan described in Fig. 1. Injection 
time was xed at 60 s and the maximum dissociation time was 350 s. Each data set was control-corrected, 
double-referenced and used for parameter tting. We also included in our analysis data we previously 
generated and published6. ose correspond to (CBS, sulphanilamide) injections at 18 °C, (BDS, sul-
fanilamide), (CBS, sulfanilamide) and (CBS, BDS) injections at 12°C (sensorgrams not shown in this 
manuscript). ree distinct models were used for comparison sake:
1. Model #1: α is chosen equal to α = MM
1
2
 (as in Mehand et al., 2012).
2. Model #2: α = RR
max1
max2
; and Rmax1, Rmax2 are obtained from separate experiments (as in Davis and Wil-
son, 2000).
3. Model #3: α is a free global parameter to be identied (our proposed method).
e three models were chosen as the rst corresponded to the one available in the manufacturer 
soware packages, in which RII are considered equal. Data were also analyzed with Model #2, where 
the ratio of the RII was determined from separate experiments, as recommended by Davis and Wilson. 
To avoid the need of this additional experiment, the third model takes into account dierences in RII 
values by introducing their ratio as a free parameter to be identied. Fits corresponding to Model #3 
are presented in Fig. 3. In all cases, in order to increase the throughput of data analysis and mimic an 
w w w .n a t u re.c o m /sc i en t i f i c repo rt s/
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automated data preparation routine, data were control-corrected without excluding any data point prior 
tting (this explains the presence of the spikes at each injection transition in Fig. 3).
e deviations of the kinetic parameters determined with each model, from those determined using a 
classical single analyte injection strategy, are presented in Table 2. As expected, we observed the highest 
deviation of the kinetic parameters when applying Model #1 - ese deviations reached more than 54% 
for several drug combinations and were correlated with bad ts as judged by visual inspection of the 
residual plots (dierence between calculated and experimental data points; data no shown). Of salient 
interest, the maximal deviation decreased to 9% when Model #2 or Model #3 were used to analyze the 
data. e kinetic parameters identied with both models were similar. e ts related to the use of Model 
#3 were judged excellent (Fig. 3 and data not shown). Of interest, Model #3 was able to describe ade-
quately the complexity of several sets of sensorgrams displaying transient maxima during the injection 
phase (Panels A, B and D of Fig.  3). is type of sensorgrams occurs when the analyte displaying the 
highest Rmax value has faster kinetic rates than those of the other analyte.
Figure 3. Kinetic analysis of multiple analyte injection experiments. Black dots correspond to control-
corrected and double referenced sensorgrams for all case studies. Red lines correspond to global ts using 
model #3. (A–G) correspond to the injection of the following analyte pairs: CBS-sulpiride, BDS-sulpiride, 
sulfanilamide-sulpiride, CBS-furosemide, BDS-furosemide, sulfanilamide-furosemide and sulpiride-
furosemide at 18 °C over CA II (5000 RU). e concentrations of CBS, BDS, sulphanilamide, sulpiride and 
furosemide were varied from 264 nM to 52.981 µ M, 52 nM to 10.494 µ M, 251 nM to 50.274 µ M, 1.37  µ M to 
275.81 µ M and 0.31 to 252.6 µ M, respectively, according to the experimental strategy described in Fig. 1. For 
all sensorgram data set, related residual plot is given below.
w w w .n a t u re.c o m /sc i en t i f i c repo rt s/
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Of salient interest, for each data set, it is possible to calculate an experimental α value (α exp, Table 1). 
e latter corresponds to the ratio of the plateau values (Rmax) corresponding to single analyte injections 
that were performed at Cmax, since these concentrations were known to correspond to saturation (see 
Fig.  1 for the experimental strategy). As can be seen in Table  1, these experimental values are in very 
good agreement with the values of α that were deduced from the global t of the various sets of sensor-
grams (α t, Table 1).
D i s c u s s i o n
In contrast to proteins, small molecular weight compounds are oen characterized by non-identical RIIs. 
ese discrepancies may translate into SPR signal amplitudes being dierent by up to two folds from 
those expected when taking into account their molecular weight and their stoichiometry of interaction 
with their bound partner15. e compounds we characterized in the present manuscript have dierent 
RIIs as deduced from the lack of linearity between the amplitudes of the SPR response at saturation 
and the analyte molecular weights (Fig. 2). While such a deviation from expected values does not aect 
the determination of the kinetic parameters when performing classical experiments (i.e., injections of 
a single analyte at various concentrations over a given surface), this RII dierence must be taken into 
account for a valid kinetic analysis of multiple-analyte injections. As originally proposed by Davis and 
Wilson (2000), the experimental determination of the various RII and the use of these values to interpret 
the data would allow for a rigorous data analysis. However, such a procedure would be detrimental to 
throughput. In order to overcome this limitation, we here demonstrate that the introduction of a global 
parameter (α ) corresponding to the ratio of the Rmax values of the dierent analytes allowed for an ade-
quate description of the mixed kinetics (Fig. 3) with deviations from kinetics obtained from a classical 
analysis of less than 10% (Table 1).
is result may appear at rst counterintuitive as increasing the number of parameters may negatively 
impact their accurate identication. Let θ,e 2 be the absolute error calculated from the estimation proce-
dure corresponding to Model #2 and θ,e 3 the absolute error calculated from Model #3. θ,e 3 is typically 
larger than θ,e 2 since the number of parameters are more. However, the value of α used in Model #2 is 
not known with certainty (due to error from the experiments that allowed its determination). e error 
in the parameter α of Model #2, αe , is computed by taking 0.3 RU error in both Rmax values. is error 
propagates into the kinetic parameters and the propagated error in kinetic parameters with Model #2, 
θ,e prop, can be calculated using
θ
α
= +
∂
∂ ( )θ θ α, ,
e e e 7prop 2
2 2
where θ
α
∂
∂
 represents the sensitivity of the kinetic parameter estimates on this global parameter α . So, a 
decrease in condence is caused in Model #3 by the increase of the number of parameters while in Model 
#2, it is due to error propagation. Calculations presented in Table 3, show that the condence of these 
two approaches are similar. us, one could use the methodology corresponding to Model #3 with the 
same condence as when determining RII experimentally, while saving experimental time and materials. 
In all the cases we studied here, the main assumption was that the analytes competed to bind to the same 
CAII site. e introduction of the α parameter could also be applied to other more complex kinetic 
models: for example, for the study of non-competitive or uncompetitive enzyme inhibition, were the 
enzyme might be the ligand while its substrate and inhibitor, the analytes.
We previously introduced the concept of multiple-analyte injections as a way to increase the through-
put of SPR biosensor devices. In that endeavour, the approach was combined to an online optimization 
algorithm to limit the duration and the number of multiple-analyte injections6. With this method, the 
experimental time and material consumption were shown to be reduced drastically. Beside the experi-
ment work reported in this manuscript, the addition of the α parameter in the kinetic model describing 
multiple-analyte injections was also tested with our online optimization approach; our results indicated 
that the throughput and the overall performances of the method were not aected. More specically, the 
introduction of the α parameter did not signicantly impact the performances of the online optimization 
algorithm since we observed the same gains in experimental time and material consumption while the 
levels of condence on the kinetic parameters were similar to those reported in this study.
Experiment Individual compound Model #2 Model #3
Sulfanilamide/Sulpiride 
(18°C)
Sulfanilamide 2.74%/1.56% 3.76%/2.18%
Sulpiride 6.72%/3.15% 5.66%/4.54%
Table 3. Calculated kinetic parameter condences computed with Model #2 and Model #3. For a given 
scenario, deviations of the kinetic parameters (ka, kd) as calculated from error propagation for Model #2 and 
Model #3.
w w w .n a t u re.c o m /sc i en t i f i c repo rt s/
8Scientific RepoRts | 5:15855 | DOi: 10.1038/srep15855
C o n c l u s i o n
e kinetic model available in the Biaevaluation soware package has been applied to analyze sensor-
grams corresponding to analyte heterogeneity13,14,20. In this model, it is hypothesized that the part of 
signal corresponding to a given analyte is proportional to its molecular weight. However, in agreement 
with previous study by Davis and Wilson (2000), this assumption does not hold true for small molecular 
weight compounds, in turn leading to biases in kinetic parameter values. While it was proposed to deter-
mine the RII ratio through additional experiments, it is shown here that the kinetic parameters could be 
obtained with similar condence without additional experimentation (thereby saving time and material) 
by treating the ratio of the RII as a global parameter to be identied.
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